Article Text

Download PDFPDF
Coronary revascularisation in patients with ischaemic cardiomyopathy
  1. Matthew Ryan1,2,
  2. Holly Morgan1,2,
  3. Mark C Petrie3,4,
  4. Divaka Perera1,2
  1. 1 Cardiovascular Division, King's College London, London, UK
  2. 2 Cardiology Department, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK
  3. 3 University of Glasgow Institute of Cardiovascular and Medical Sciences, Glasgow, UK
  4. 4 Cardiology Department, Golden Jubilee National Hospital, Clydebank, UK
  1. Correspondence to Professor Divaka Perera, Cardiology, St. Thomas Hospital, London SE1 7EH, UK; divaka.perera{at}


Heart failure resulting from ischaemic heart disease is associated with a poor prognosis despite optimal medical treatment. Despite this, patients with ischaemic cardiomyopathy have been largely excluded from randomised trials of revascularisation in stable coronary artery disease. Revascularisation has multiple potential mechanisms of benefit, including the reversal of myocardial hibernation, suppression of ventricular arrhythmias and prevention of spontaneous myocardial infarction. Coronary artery bypass grafting is considered the first-line mode of revascularisation in these patients; however, evidence from the Surgical Treatment of Ischaemic Heart Failure (STICH) trial showed a reduction in mortality, though this only became apparent with extended follow-up due to an excess of early adverse events in the surgical arm. There is currently no randomised controlled trial evidence for percutaneous coronary intervention in patients with ischaemic cardiomyopathy; however, the REVIVED-BCIS2 trial has recently completed recruitment and will address this gap in the evidence. Future directions include (1) clinical trials of revascularisation in patients hospitalised with heart failure, (2) defining the role of viability and ischaemia testing in heart failure, (3) studies to enhance the understanding of the mechanistic effects of revascularisation and (4) generating models to refine pre- and post-revascularisation risk prediction.

  • coronary artery disease surgery
  • percutaneous coronary intervention
  • chronic coronary disease
  • heart failure with reduced ejection fraction

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @drmattryan

  • Contributors MR, HM, MCP and DP conceived, drafted, reviewed and edited the article.

  • Funding This article was supported by the British Heart Foundation via a fellowship grant (FS 18/16/33396) and the Centre of Research Excellence Award to King’s College London and by the National Institute for Health Research via the Biomedical Research Centre Award to Guy’s and St Thomas’ Hospital and King’s College London.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.